secwatch.observer — SEC 8-K summary
======================================

Issuer:     BeOne Medicines Ltd. (ONC)
CIK:        0001651308
Form:       8-K
Filed at:   2024-11-12T23:59:59+00:00
Accession:  0001651308-24-000150
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BeiGene Q3 revenue $1.0B (+28% YoY); BRUKINSA global revenue $690M; positive non-GAAP OP income
--------------------------------------------------------------------------------

- Total revenue $1,001.6M (+28% YoY); product revenue $993.4M (+67% YoY).
- GAAP operating loss narrowed to $120.3M from $134.0M; adjusted operating income $65.6M vs loss $16.3M.
- BRUKINSA global revenue $690M; now #1 in new patient starts for frontline and R/R CLL in U.S.
- Four NMEs entered clinic in Q3 (eight YTD); on track for 10+ in 2024; sonrotoclax & BGB-16673 in late-stage.
- CEO cites strong momentum in hematology and solid tumor pipeline expansions globally.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1651308/000165130824000150/0001651308-24-000150-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1651308/000165130824000150/bgne-20241112.htm
  HTML page:      https://secwatch.observer/filing/0001651308-24-000150

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer